Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264086 | 1.00 | PNP (0.39) | PNPADORA2ACYP3A4MAPTMEN1 | |
| SCHEMBL14626327 | 0.89 | PNP (0.34) | PNP | |
| SCHEMBL13847074 | 0.88 | PNP (0.34) | PNP | |
| SCHEMBL264671 | 0.85 | HPRT1 (0.41) | — | |
| SCHEMBL3365046 | 0.81 | PNP (0.54) | PNP | |
| SCHEMBL3365040 | 0.81 | PNP (0.54) | PNP | |
| SCHEMBL264095 | 0.81 | PNP (0.36) | PNPADORA2A | |
| SCHEMBL3304026 | 0.81 | PNP (0.36) | PNPADORA2A | |
| SCHEMBL259613 | 0.81 | PNP (0.36) | PNPADORA2A | |
| SCHEMBL264662 | 0.80 | ADORA2A (0.41) | ADORA2AADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | PNP 8/4885ADORA2A 134/4885CYP3A4 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.